 ABINGDON, OXFORDSHIRE ACCESSWIRE March 2, 2020 Midatech Pharma PLC AIM: MTPH.L; Nasdaq: MTP, an RD; biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has received regulatory and ethics approval to commence a further exploratory Phase I study for its MTX110 drug for diffuse midline glioma brain tumours, to be conducted at Columbia University in New York. The Columbia study will administer MTX110 via a small subcutaneously implanted pump sited in the abdominal wall, that infuses MTX110 directly to the brain tumour via tubing routed under the skin to the base of the brain. The Convection Enhanced Delivery CED system is designed to facilitate chronic infusion of intracerebral chemotherapy directly into the brain. 